Please login to the form below

Not currently logged in
Email:
Password:

Astellas withdraws drug application in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan

Astellas Pharma has withdrawn the marketing application for its venous thromboembolism preventative darexaban in Japan, the first market in which it had filed the drug.

The marketing application, which was submitted in late September 2010, had been seeking approval of the oral Factor Xa direct inhibitor for the prevention of venous thromboembolism (VTE) in patients at risk, such as those undergoing orthopaedic surgical procedures in the lower limbs.

Astellas said it was withdrawing the application based on feedback from Japanese regulators that additional clinical trials would be required before the drug could be approved. The marketing application contained two phase II/III studies that compared darexaban to placebo in patients who had elective total knee or hip replacement surgeries in Japan and other Asian countries.

In addition, a North American phase II study for VTE prevention in patients after elective primary knee arthroplasty demonstrated dose-dependent efficacy in VTE prevention, according to the company.

Astellas said it will seek a partner for the development and commercialisation of darexaban for the VTE indication in the US and Europe and for an indication of stroke prevention in atrial fibrillation globally. "Astellas expects to decide future plans, including the indication of VTE in Japan, based on the outcome of the partnership discussion," the company noted.

Darexaban, which was discovered and developed by Astellas, works by directly and selectively inhibiting activated Factor X in the cascade of blood coagulation.

16th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics